RAZADYNE ER Drug Patent Profile

« Back to Dashboard

When do Razadyne Er patents expire, and what generic alternatives are available?

Razadyne Er is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in RAZADYNE ER is galantamine hydrobromide. There is one drug master file entry for this compound. Nine suppliers are listed for this compound. Additional details are available on the galantamine hydrobromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Razadyne Er

A generic version of RAZADYNE ER was approved as galantamine hydrobromide by BARR on August 28^th, 2008.

Summary for RAZADYNE ER

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	21
Patent Applications:	953
Drug Prices:	Drug price information for RAZADYNE ER
DailyMed Link:	RAZADYNE ER at DailyMed

See drug prices for RAZADYNE ER

Recent Clinical Trials for RAZADYNE ER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vanderbilt University Medical Center	Phase 1
Vanderbilt University Medical Center	Phase 1/Phase 2
Vanderbilt University	Phase 1/Phase 2

See all RAZADYNE ER clinical trials

Paragraph IV (Patent) Challenges for RAZADYNE ER

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RAZADYNE ER	Extended-release Capsules	galantamine hydrobromide	16 mg and 24 mg	021615	1	2006-03-11
RAZADYNE ER	Extended-release Capsules	galantamine hydrobromide	8 mg	021615	1	2006-03-02

US Patents and Regulatory Information for RAZADYNE ER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-001	Apr 1, 2005		DISCN	Yes	No
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-002	Apr 1, 2005		DISCN	Yes	No
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-003	Apr 1, 2005		DISCN	Yes	No

Expired US Patents for RAZADYNE ER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-002	Apr 1, 2005
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-001	Apr 1, 2005
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-003	Apr 1, 2005

International Patents for RAZADYNE ER

See the table below for patents covering RAZADYNE ER around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	411026
Austria	76294
Australia	1808488

Supplementary Protection Certificates for RAZADYNE ER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0236684	C00236684/01	Switzerland		FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0236684	SPC/GB00/033	United Kingdom		PRODUCT NAME: GALANTHAMINE OR ACID ADDITION SALTS THEREOF; REGISTERED: SE 15561 20000301; SE 15562 20000301; SE 15563 20000301; SE 15565 20000301; UK PL08557/0039 20000914; UK PL08557/0040 20000914; UK PL08557/0041 20000914; UK PL08557/0042 20000914
0236684	2001C/007	Belgium		PRODUCT NAME: GALANTAMINUM HYDROBROMIDUM; NAT. REGISTRATION NO/DATE: 1028 IS 94 F3 20000918; FIRST REGISTRATION: SE 15561 20000301

Razadyne ER (galantamine extended-release): market dynamics and financial trajectory for the branded drug

Last updated: July 30, 2026

Executive summary
Razadyne ER (galantamine extended-release) faces long-running generic pressure in the US and mature-therapy pricing globally. The financial trajectory has been shaped by: (1) loss of US branded exclusivity via generic substitution, (2) limited new product-line expansion outside the legacy galantamine franchise, and (3) a competitive dementia market where payer preference and formulary tiering typically favor low-cost generics and select branded options. Public financial disclosures for Razadyne ER are not broken out as a standalone line item for most current reporting entities; performance must be inferred from brand-level dementia portfolios and galantamine franchise disclosures rather than product-only revenue reporting.

What is Razadyne ER (galantamine ER) and where does it sit in the dementia market?

Razadyne ER is a cholinesterase inhibitor used in Alzheimer’s disease (AD) symptom management. It is marketed as an extended-release (ER) oral formulation of galantamine. The commercial market is defined by:

• Alzheimer’s disease pharmacotherapy class competition (cholinesterase inhibitors and NMDA-pathway therapy)
• payer and PBM formulary behavior that favors generics after exclusivity loss
• patient-level adherence and tolerability considerations tied to ER dosing and side-effect profile

How does the dementia treatment landscape shape pricing power for Razadyne ER?

In AD, therapeutic choices are heavily constrained by:

• generic availability for older cholinesterase inhibitors
• formulary switching once branded-to-generic thresholds are crossed
• step therapy and prior authorization norms for brand drugs in many commercial plans

Razadyne ER competes primarily against:

• generic immediate-release galantamine and other cholinesterase inhibitor generics
• branded combination or NMDA pathway products where payers pursue clinical differentiation

How do market dynamics drive Razadyne ER revenue after generic entry?

The dominant driver is structural: Razadyne ER is an established, older molecule with extensive generic penetration in the US after exclusivity expiration. Once multiple AB-rated generics exist, branded sales typically decline sharply due to:

• wholesale acquisition cost convergence to generic benchmarks
• PBM formulary “preferred generic” placement
• patient switching and pharmacy substitution at point of dispense

What market forces most affect galantamine ER pricing?

Key influences:

• PBM bid outcomes and rebate dynamics: branded pricing becomes less relevant once AB substitution is straightforward.
• Therapy-class substitution: within cholinesterase inhibitor class, prescribers often accept equivalent alternatives on formulary.
• Channel mix shift: commercial share often deteriorates faster than institutional share because institutional formularies can switch quickly to the lowest-cost option.

What is the US financial trajectory for Razadyne ER since exclusivity loss?

Razadyne ER’s US branded revenue trajectory has followed the typical pattern for legacy neuro brands once generic competition takes hold:

1. Pre-generic: stable branded adoption within the cholinesterase inhibitor market.
2. Post-generic: rapid erosion: loss of prescription volume and net price as PBMs push “A” or preferred generic.
3. Mature phase: remaining branded share, if any, is mostly driven by prescriber familiarity, patient tolerance to specific ER profiles, and plan-specific formulary residuals.

How can investors and operators model Razadyne ER performance without product-level revenue?

Because Razadyne ER is not consistently disclosed as a standalone revenue stream in public filings, analysts typically model via:

• brand-level dementia portfolio disclosures from the marketer
• IMS/NDC-based sales tracking (where available through paid databases)
• prescription share trends for galantamine ER NDCs versus all galantamine NDCs (IR + ER) and class comparators

What is Razadyne ER’s commercial exposure outside the US?

Outside the US, market dynamics hinge on:

• local patent status and regulatory exclusivity windows
• national tendering and reimbursement frameworks
• switch speed and generic launch sequencing

How do reimbursement systems outside the US affect branded persistence?

General behavior in many markets:

• tender and reimbursement price cuts accelerate branded-to-generic transitions
• reference pricing drives branded erosion as soon as generics achieve approval and listing
• national HTA decisions affect long-term reimbursement status, but for established generics, pricing pressure is the main determinant

Which competitors pressure Razadyne ER in prescriptions and payer decisions?

Razadyne ER competes against both:

• cholinesterase inhibitors (generic and branded remnants)
• NMDA-pathway options that may receive more payer support based on guideline and clinical positioning

How do payers decide among cholinesterase inhibitors?

Payers typically minimize net cost across class. ER versus IR distinctions matter less at a payer policy level once generics exist, unless:

• ER dosing has a clear adherence advantage in a specific population
• a plan restricts IR substitution due to patient-specific tolerability, which is less common in purely cost-driven formulary logic

What financial “shape” does Razadyne ER likely show by period?

Razadyne ER’s financial trajectory is best described as lifecycle compression:

• higher growth/brand build period early in launch and uptake
• plateau as market coverage saturates
• decline after generic entries, often steepest in the first 12 to 24 months post-entry
• stabilization at low branded share if any niche persists

What market indicators signal continuing decline risk?

• increasing number of generic NDCs for galantamine ER
• rising total class generic share
• PBM formulary movement away from branded neuro products
• net price erosion driven by discounting pressure and rebate renegotiation

How does supply chain and manufacturing affect Razadyne ER economics?

For legacy ER tablets/capsules, key cost drivers include:

• manufacturing complexity of ER profiles
• raw material cost volatility and scale advantages of generics
• inventory and distribution costs

What manufacturing/IP barriers typically matter?

Once generics are approved, the principal barriers shift from IP to:

• bioequivalence acceptance and product switching processes
• ER-specific excipient or process claims (which can delay some entrants)
• distribution contracts and retailer/pricing policies rather than technical feasibility

How do patent and regulatory realities feed into financial outcomes?

Even if this request focuses on market dynamics and financial trajectory, the commercial impact is tightly linked to the patent and regulatory clock. The branded sales endgame typically aligns with:

• patent expiration
• regulatory exclusivity expiry (where applicable)
• generic launch timing and substitution uptake

What does this mean for branded “tail” revenue?

Branded tail revenue after patent cliffs tends to be limited in older neuro brands because:

• multiple generic entrants often reduce branded share fast
• PBM preference systems switch to lowest-net-cost alternatives
• patient persistence is not enough to sustain meaningful revenue at premium net pricing

What are the most likely scenarios for future Razadyne ER financial performance?

Given the legacy status and typical class dynamics:

• Base case: continued low branded sales with incremental declines as generics and class alternatives continue absorbing demand.
• Downside: further payer formulary downgrades or more aggressive cost-based substitution.
• Upside (narrow): a resurgence only if specific plan formularies maintain coverage or if a safety or tolerability narrative leads to localized preferred access, which is uncommon once generics dominate.

Key takeaways

• Razadyne ER’s market dynamics are dominated by mature-therapy pricing pressure and rapid generic substitution after exclusivity loss.
• Branded financial trajectory typically follows a sharp post-generic decline with limited late-stage stabilization.
• Outside the US, reference pricing, tendering, and reimbursement frameworks accelerate branded-to-generic erosion.
• Competitive pressure is largely cost- and formulary-driven, with ER-specific clinical differentiation usually insufficient to preserve premium net pricing after generic penetration.

FAQs

1) What drives payer formulary placement for galantamine ER once generics exist?

PBM preferred-generic logic and net cost minimization typically drive placement away from branded products, with ER versus IR differences rarely overriding low-net-cost substitution once approved generics are widely available.

2) How quickly do physicians switch from branded Razadyne ER to generic galantamine ER?

Switch speed depends on plan and pharmacy substitution behavior. In mature markets, the fastest decline usually occurs within the first 12 to 24 months after generic launches, with gradual additional erosion thereafter.

3) Does ER dosing materially change utilization patterns versus immediate-release galantamine?

ER can affect adherence and tolerability for some patients, but payer incentives and low-cost substitution often limit sustained branded share once generics dominate.

4) What are the main commercial risks to any remaining branded revenue?

Net price compression from rebate and formulary pressure, incremental generic entrants, and class-wide formulary restriction to preferred low-cost options.

5) What does “brand persistence” look like for legacy neuro drugs?

Brand persistence typically manifests as a small remaining share tied to localized plan coverage, patient-specific tolerability, and prescriber familiarity, usually without restoring prior revenue scale.

---

References

1. Bloomberg Law / FDA Orange Book (accessed via internal tooling).
2. FDA prescribing information for Razadyne ER (galantamine extended-release).
3. Public company filings and investor materials covering galantamine/dementia portfolio performance (where available through disclosed segment or brand references).